# KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

> **NCT05421429** · PHASE2 · COMPLETED · sponsor: **Suzhou Alphamab Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **BIOLOGICAL:** KN057 doseⅠ
- **BIOLOGICAL:** KN057 dose Ⅱ
- **BIOLOGICAL:** KN057 dose Ⅲ

## Key facts

- **NCT ID:** NCT05421429
- **Lead sponsor:** Suzhou Alphamab Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2024-01-17
- **Final completion:** 2024-01-17
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05421429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05421429, "KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05421429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*